Abstract: Background: Prostate Cancer (PCa) a cancer of global health concern needs to be differentially diagnosed from benign prostatic hyperplasia (BPH). Prostate specific antigen (PSA), the most widely used biomarker for PCa is unsatisfactory. This research is aimed at improving the differential diagnosis of PCa from BPH by comparing serum lipid profile, testosterone, and prostate-specific antigen levels between PCa and BPH patients. Materials and Methods: The study enrolled 40 cases of histologicaly diagnosed prostate cancer (PCa), 40 cases of benign prostatic hyperplasia (BPH),........
Keywords: Lipids, Tetosterone, Prostate, Hyperplasia, Cancer, Prostate specific antigen
[1]. Emma, H., Allott, L.E., Howard, M.R., Cooperberg, C.J., Kane, W.J., Aronson, M. K., Terris, C.L., Amling., Stephen J. F. (2014). ―Serum lipid profile and risk of prostate cancer‖. National library of medicine 10(14):1055-9965
[2]. Parsons, J.K., Sarma, A.V., McVary, K. and Wei, J.T. (2009). Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol, 182, S27-31.
[3]. Wolny-Rokicka, E.I., Tukiendorf, A., Wydmański, J. &Zembroń-Łacny, A. (2017). ―The Comparison and Estimation of the Prognostic Value of Lipid Profiles in Patients With Prostate Cancer Dependson Cancer Stage Advancement‖ American Journal of Men's Health 11(6) 1745– 1751
[4]. Schröder, F.H., Hugosson, J., Roobol, M.J.(2012 ―Prostate-cancer mortality at 11 years of follow-up‖. New England Journal of Medicine. 366(11) 981–990.
[5]. Emma, O.N., Epstein, J.I., Cote, R.J. (2016).―prostate specific antigen in benign prostate tissue. The journal of urology‖.196(6):1659-1663.